A noteworthy advancement in targeted therapy is MRTX1133 (Wang et al., 2022), demonstrating potential in inhibiting KRAS G12D and introducing novel avenues for pancreatic cancer treatment. This evidence concerns the gene KRAS and familial pancreatic carcinoma.